Achieve Life Sciences, Inc. (ACHV) |
| 5.24 -0.06 (-1.13%) 05-29 16:00 |
| Open: | 5.375 |
| High: | 5.49 |
| Low: | 5.235 |
| Volume: | 967,109 |
| Market Cap: | 538(M) |
| PE Ratio: | -4.9 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 7.18 |
| Resistance 1: | 6.15 |
| Pivot price: | 5.12 |
| Support 1: | 4.78 |
| Support 2: | 3.93 |
| 52w High: | 6.15 |
| 52w Low: | 2 |
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Financials
| EPS | -1.070 |
| Book Value | 0.200 |
| PEG Ratio | 17.68 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -108.4 |
| Return on Equity (ttm) | -496.1 |
Company news
Fri, 29 May 2026
Achieve Life Sciences (ACHV) asks shareholders to double authorized common shares to 300M - Stock Titan
Fri, 29 May 2026
Achieve Life Sciences 4Q Loss/Shr 28c >ACHV - Moomoo
Wed, 13 May 2026
[Form 3] ACHIEVE LIFE SCIENCES, INC. Initial Statement of Beneficial Ownership | ACHV Insider Trading - Stock Titan
Tue, 12 May 2026
Investors commit $354M to Achieve Life's potential new stop-smoking drug - Stock Titan
Tue, 12 May 2026
Achieve Life Sciences Strengthens Board and Commercial - GlobeNewswire
Tue, 05 May 2026
Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday - MarketBeat
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
